POZEN Inc. (POZN) Receives Decision from AstraZeneca (AZN) to File PN 400 NDA
More News related to AZN
- Widespread Generic Erosion of Atypical Antipsychotics Will Cause the Bipolar Disorder Drug Market to Decline By More Than $1 Billion Through 2018
- Quintiles and AstraZeneca (AZN) Enter into Pharmacology Alliance
- Semi-Annual Changes to the NASDAQ OMX CRD Global Sustainability 50 Index
- AstraZeneca's (AZN) MedImmune to Present 4 Abstracts on RSV and Influenza at 47th Annual IDSA Meeting
- MedImmune to Present Four Abstracts on RSV and Influenza at 47th Annual IDSA Meeting
More News related to POZN
- POZEN To Present at the Credit Suisse Healthcare Conference
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- POZEN (POZN) Beats Estimates by 5c, Reports Q3 EPS of $0.22
- POZEN Reports Third Quarter 2009 Results
- POZEN (POZN) PA65020 Phase I Shows Risk Reduction in Upper Gastrodudenal Damage
POZEN Inc. (NASDAQ: POZN) reported that AstraZeneca (NYSE: AZN) has made the decision to have POZEN file the New Drug Application (NDA) for PN 400 with the FDA. POZEN continues to target a mid-2009 NDA filing and expects to receive a milestone payment of $10 million when the NDA is formally accepted for submission by the FDA.
The license agreement executed with AstraZeneca in August 2006 established a Phase III clinical development program for PN 400, an investigational compound, that combines the pain reliever naproxen (an NSAID) with esomeprazole magnesium, a proton pump inhibitor (PPI), to support a potential indication for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing gastric ulcers.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.05
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
